This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Cong Li
The First Affiliated Hospital of Chongqing Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8234-2121
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Purpose To explore the value of anti-Mullerian hormone (AMH) in polycystic ovary syndrome (PCOS) patients for different phenotype and age, and identify the relationship between the hyperandrogenism (HA) and polycystic ovary morphology (PCOM) in Chinese cohort.
Methods A total of 2262 women (1631 with PCOS and 631 health controls) were enrolled. The serum AMH and total testosterone (TT) were analyzed, compared the AMH level of each subgroup and evaluated the value of each phenotype and age group of PCOS.
Results The level of AMH in PCOS(8.63±4.73ng/ml) was higher than that in health controls(5.57±3.31ng/ml) (P＜0.01).The level of AMH in PCOM subgroup(11.19±6.4ng/ml) was significantly higher than that in HA subgroup(8.58±4.74ng/ml) (P＜0.01), and both higher than that in health controls(P＜0.01). AMH changes highly in PCOS compared with the health control, but as the same value in subgroups of PCOS patients under 30-year-old.
Conclusion AMH changed in different subgroups of PCOS, which was the possible reason why AMH was not a diagnostic indicator. However, AMH could differ the subgroup in clinical, AMH was strongly related with PCOM, not hyperandrogenism. AMH changed much as aged, but stable in PCOS patients under 30-year-old.
Keywords
anti-Mullerian hormone, polycystic ovary syndrome, hyperandrogenism, polycystic ovary morphology
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 28 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Endocrinology & Metabolism
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
Cong Li
The First Affiliated Hospital of Chongqing Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8234-2121
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 28 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Endocrinology & Metabolism
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Purpose To explore the value of anti-Mullerian hormone (AMH) in polycystic ovary syndrome (PCOS) patients for different phenotype and age, and identify the relationship between the hyperandrogenism (HA) and polycystic ovary morphology (PCOM) in Chinese cohort.
Methods A total of 2262 women (1631 with PCOS and 631 health controls) were enrolled. The serum AMH and total testosterone (TT) were analyzed, compared the AMH level of each subgroup and evaluated the value of each phenotype and age group of PCOS.
Results The level of AMH in PCOS(8.63±4.73ng/ml) was higher than that in health controls(5.57±3.31ng/ml) (P＜0.01).The level of AMH in PCOM subgroup(11.19±6.4ng/ml) was significantly higher than that in HA subgroup(8.58±4.74ng/ml) (P＜0.01), and both higher than that in health controls(P＜0.01). AMH changes highly in PCOS compared with the health control, but as the same value in subgroups of PCOS patients under 30-year-old.
Conclusion AMH changed in different subgroups of PCOS, which was the possible reason why AMH was not a diagnostic indicator. However, AMH could differ the subgroup in clinical, AMH was strongly related with PCOM, not hyperandrogenism. AMH changed much as aged, but stable in PCOS patients under 30-year-old.
Loading...